Pura Vida Investments’s Cullinan Oncology CGEM Stock Holding History

Pura Vida Investments’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-45,900	Closed	-$481K	–	222
2022 Q1	$481K	Buy	+45,900	New	+$620K	0.02%	203

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Pura Vida Investments's CGEM Position: Q4 2021 in Review

Pura Vida Investments sold out of Cullinan Oncology (CGEM) in Q4 2021, closing a stake of 81,418 shares — an estimated $1.84M sold.

Pura Vida Investments first reported a position in CGEM in Q1 2021 and held it in 3 quarters. The position peaked at $9.03M in Q1 2021. 75 funds tracked by Wall St. Rank hold CGEM as of Q4 2021.

Pura Vida Investments reported no remaining Cullinan Oncology position as of Q4 2021 after selling out during the quarter.
Pura Vida Investments sold 81,418 Cullinan Oncology shares in Q4 2021, an estimated $1.84M.
Pura Vida Investments first reported a position in Cullinan Oncology in Q1 2021 and held it in 3 quarters.
Pura Vida Investments's Cullinan Oncology position peaked at $9.03M in Q1 2021.
75 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2021.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.